CY1112057T1 - Θεραπευτικος παραγων για διαταραχη επαρκειας τροφης στο στομαχι - Google Patents

Θεραπευτικος παραγων για διαταραχη επαρκειας τροφης στο στομαχι

Info

Publication number
CY1112057T1
CY1112057T1 CY20111101103T CY111101103T CY1112057T1 CY 1112057 T1 CY1112057 T1 CY 1112057T1 CY 20111101103 T CY20111101103 T CY 20111101103T CY 111101103 T CY111101103 T CY 111101103T CY 1112057 T1 CY1112057 T1 CY 1112057T1
Authority
CY
Cyprus
Prior art keywords
therapeutic products
automatic administration
administration
automatic
general formula
Prior art date
Application number
CY20111101103T
Other languages
Greek (el)
English (en)
Inventor
Yugo Matsunaga
Shigeru Ueki
Raita Higashino
Masanao Kawachi
Hiroki Kato
Shiro Kobayashi
Original Assignee
Zeria Pharmaceutical Co., Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=28786350&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1112057(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zeria Pharmaceutical Co., Ltd filed Critical Zeria Pharmaceutical Co., Ltd
Publication of CY1112057T1 publication Critical patent/CY1112057T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CY20111101103T 2002-04-08 2011-11-16 Θεραπευτικος παραγων για διαταραχη επαρκειας τροφης στο στομαχι CY1112057T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002104894 2002-04-08
EP03745958A EP1493441B1 (en) 2002-04-08 2003-04-08 Therapeutic agent for food competence disorder in stomach

Publications (1)

Publication Number Publication Date
CY1112057T1 true CY1112057T1 (el) 2015-11-04

Family

ID=28786350

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111101103T CY1112057T1 (el) 2002-04-08 2011-11-16 Θεραπευτικος παραγων για διαταραχη επαρκειας τροφης στο στομαχι

Country Status (14)

Country Link
US (4) US20050176788A1 (cg-RX-API-DMAC7.html)
EP (2) EP2301540A1 (cg-RX-API-DMAC7.html)
JP (2) JP5281226B2 (cg-RX-API-DMAC7.html)
KR (4) KR101423284B1 (cg-RX-API-DMAC7.html)
CN (2) CN1646123A (cg-RX-API-DMAC7.html)
AT (1) ATE522214T1 (cg-RX-API-DMAC7.html)
AU (1) AU2003236326B2 (cg-RX-API-DMAC7.html)
CA (1) CA2481916C (cg-RX-API-DMAC7.html)
CY (1) CY1112057T1 (cg-RX-API-DMAC7.html)
DK (1) DK1493441T3 (cg-RX-API-DMAC7.html)
ES (1) ES2368732T3 (cg-RX-API-DMAC7.html)
PT (1) PT1493441E (cg-RX-API-DMAC7.html)
SI (1) SI1493441T1 (cg-RX-API-DMAC7.html)
WO (1) WO2003084537A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104447612A (zh) * 2013-09-16 2015-03-25 天津市汉康医药生物技术有限公司 阿考替胺水合物晶型及其制备方法和用途
CN103980226A (zh) * 2014-05-10 2014-08-13 杭州新博思生物医药有限公司 盐酸阿考替胺水合物晶型及其制备方法
CN105315225A (zh) * 2014-07-07 2016-02-10 中美华世通生物医药科技（武汉）有限公司 阿考替胺的酸加成盐及其制备方法
CN104045606B (zh) * 2014-07-11 2015-09-30 杭州新博思生物医药有限公司 一锅法制备阿考替胺盐酸盐的方法
CN109988121B (zh) * 2019-04-28 2023-01-03 梯尔希（南京）药物研发有限公司 一种阿考替胺衍生物的制备方法
MX2024000751A (es) 2021-07-14 2024-03-25 Blueprint Medicines Corp Compuestos heterociclicos como inhibidores de map4k1.

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1063442C (zh) * 1995-05-18 2001-03-21 泽里新药工业株式会社 氨基噻唑衍生物、含有它们的药物组合物及其用途
JPH10212271A (ja) * 1997-01-31 1998-08-11 Zeria Pharmaceut Co Ltd Ｎ−置換ベンゾイルアミン誘導体、それを含有する医薬及び該化合物の製造中間体
PT994108E (pt) * 1997-06-24 2003-09-30 Zeria Pharm Co Ltd Processo de producao de derivados de 2-hidroxibenzamida
US5981556A (en) * 1997-07-22 1999-11-09 G.D. Searle & Co. 1,3-diazolino and 1,3-diazolidino heterocycles as useful nitric oxide synthase inhibitors
NZ511117A (en) * 1998-11-23 2002-11-26 Janssen Pharmaceutica Nv Use of prucalopride for the manufacture of a medicament for the treatment of dyspepsia
JP2003501427A (ja) * 1999-06-02 2003-01-14 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ アミノアルキル置換（ベンゾジオキサン、ベンゾフランもしくはベンゾピラン）誘導体
CA2391497C (en) * 1999-11-23 2008-12-30 Janssen Pharmaceutica N.V. Use of 5ht3 agonists for relaxing the fundus
GB0002336D0 (en) * 2000-02-01 2000-03-22 Glaxo Group Ltd Medicaments
JP4876367B2 (ja) * 2000-09-08 2012-02-15 ゼリア新薬工業株式会社 アミノチアゾール誘導体を有効成分とする大腸運動不全治療剤
US6986882B2 (en) * 2002-01-17 2006-01-17 Astrazeneca Ab Therapy for functional dyspepsia

Also Published As

Publication number Publication date
KR20120037035A (ko) 2012-04-18
KR101423284B1 (ko) 2014-07-24
AU2003236326B2 (en) 2008-02-28
ES2368732T3 (es) 2011-11-21
JP5281226B2 (ja) 2013-09-04
PT1493441E (pt) 2011-09-28
EP1493441B1 (en) 2011-08-31
JP2011068692A (ja) 2011-04-07
CA2481916C (en) 2013-02-26
EP1493441A1 (en) 2005-01-05
DK1493441T3 (da) 2011-10-17
JPWO2003084537A1 (ja) 2005-08-11
US20090156652A1 (en) 2009-06-18
KR20130101162A (ko) 2013-09-12
KR20050002925A (ko) 2005-01-10
EP1493441A4 (en) 2007-10-17
ATE522214T1 (de) 2011-09-15
US20200375954A1 (en) 2020-12-03
KR20110010837A (ko) 2011-02-07
JP5360075B2 (ja) 2013-12-04
WO2003084537A1 (en) 2003-10-16
US20150141475A1 (en) 2015-05-21
CA2481916A1 (en) 2003-10-16
EP2301540A1 (en) 2011-03-30
CN1646123A (zh) 2005-07-27
AU2003236326A1 (en) 2003-10-20
SI1493441T1 (sl) 2011-12-30
CN102125551B (zh) 2015-07-22
CN102125551A (zh) 2011-07-20
US20050176788A1 (en) 2005-08-11

Similar Documents

Publication Publication Date Title
EE200300403A (et) N-asendatud mittearomaatne heterotsükliline ühend, seda sisaldav ravimkompositsioon ning ühendi kasutamine ravimina
HRP20090281T1 (hr) 1,2,3,4-tetrasubstituirani indol za liječenje respiratornih bolesti
JO2371B1 (en) 4-phenyl-pyridine derivatives
MY148480A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
BRPI0511504A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, e, agente preventivo ou terapêutico para uma doença resultante de beta-amilóides
WO2005046603A3 (en) Pyridine compounds
GEP20074208B (en) Substituted amides active at the cannabinoid-1 receptor
NO20043367L (no) Oralt farmasoytisk preparat
TW200621737A (en) 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof
EA200500377A1 (ru) Пиразольные производные как ингибиторы трансформирующего фактора роста (tgf)
CY1112057T1 (el) Θεραπευτικος παραγων για διαταραχη επαρκειας τροφης στο στομαχι
HK1046405A1 (zh) 作为nmda受体拮抗剂用於治疗疼痛的取代的1，5-二氢吡咯-2-酮衍生物
UA84896C2 (ru) Производные гидронопола как агонисты человеческих рецепторов orl1
MXPA05006889A (es) Compuestos aromaticos como agentes anti-inflamatorios, inmunomoduladores y anti-proliferativos.
DE69834500D1 (de) Xanthinderivative zur behandlung von hirnischämie
DK1228758T3 (da) Anvendelse af sulfodehydroabietinsyre til behandling af inflammatorisk tarmsygdom
EP1329451A4 (en) SPIRO COMPOUNDS AND THESE ADHESIVE MOLECUIN INHIBITORS CONTAINING ACTIVE SUBSTANCE
TW200509992A (en) Dosage form containing pantoprazole as active ingredient
EP1426360A4 (en) 2-PHENYL-3-HETEROARYLPROPIONIC ACID DERIVATIVE OR SALT THEREOF AND MEDICAMENTS CONTAINING THE SAME
MY139228A (en) Imidazolinylmethyl aralkylsulfonamides
BR0207102A (pt) Forma cristalina, composição farmacêutica, uso de uma forma cristalina, e, método para a prevenção ou o tratamento de doença
AU2001246999A1 (en) New neurokinin antagonists for use as medicaments
TW200503785A (en) Dosage form containing (S)-pantoprazole as active ingredient
TW200519102A (en) Hydronopol substituted benzimidazolone and quinazolinone derivatives as agonists on human ORL1 receptors
WO2004048381A3 (en) Pyrazoloazepine compounds as pharmaceutical agents